The present invention relates to an improved process for the preparation of 4-acetyl-2-methyl- benzonitrile of formula (I). The present invention further provides an improved process for the preparation of isoxazoline derivatives using 4-acetyl-2-methyl-benzonitrile of formula (I) obtained by a process described herein.
C07C 253/14 - Preparation of carboxylic acid nitriles by reaction of cyanides with halogen-containing compounds with replacement of halogen atoms by cyano groups
C07C 255/50 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
2.
A SUBSTANTIALLY PURE FLUAZURON AND PREPARATION THEREOF
The present invention relates to substantially pure Fluazuron. The substantially pure Fluazuron comprises one or more impurities selected from di-pyridine impurity, diamide impurity and dimer impurity. The present invention further relates to a process for the preparation of substantially pure Fluazuron of formula (I) with purity greater than 99.5% comprising one or more impurities selected from di-pyridine impurity of formula (1) less than 0.15%, diamide impurity of formula (2) is less than 0.15%, and dimer impurity of formula (3) less than 0.2% as measured by HPLC. Formula (I), Formula (1), Formula (2), Formula (3).
The present invention relates to a process for the preparation of isoxazoline-substituted amide compounds and its intermediates thereof. The present invention, particularly, relates to a process for the preparation of isoxazoline- substituted amide compounds such as Fluralaner, Afoxolaner or Lotilaner and its intermediates thereof.
C07D 261/04 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
4.
AN INDUSTRIAL PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 2,3-O-ISOPROPYLIDENE-D-RIBOFURANOSE
The present invention relates to an industrial process for the preparation of 2,3-O-Isopropylidene-D-ribofuranose of formula (I). The intermediate of formula (I) is used for the preparation of Varitriol, Carbovir, Abacavir, Sapropterin dihydrochloride, L-Biopterin. The process of present invention provides the 2,3-O-Isopropylidene-D-ribofuranose of formula (I) having purity at least 98%.
C07H 1/00 - Processes for the preparation of sugar derivatives
C07H 9/02 - Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
5.
NOVEL INTERMEDIATES AND ITS USE IN MANUFACTURING OF SITAGLIPTIN
The present invention relates to novel intermediate of formula (V) and formula (VI) and preparation thereof. The present invention further relates to an industrially feasible and commercially viable process for preparation of sitagliptin or its pharmaceutically acceptable salts using novel intermediates of formula (V) and formula (VI) in high yield with greater chemical and chiral purity.
C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
The present invention relates to an industrial scale process for the preparation and crystallization of polymorphic form-I of Prothioconazole formula (I) in high yield and greater chemical purity.
The present invention relates to an industrial scale process for the preparation of Prothioconazole (I), which is simple, economical, efficient, user and environment friendly, moreover commercially viable with higher yield and greater chemical purity.
The present invention relates to substantially pure Clarithromycin 9-oxime more particularly Clarithromycin 9(E)-oxime having purity more than 98% and corresponding (Z)-isomer not more than 1%. The present invention further relates to a process for preparation of Clarithromycin 9(E)-oxime of formula (I), its pharmaceutically acceptable salts and purification.
The present invention relates to substantially pure Clarithromycin 9-oxime more particularly Clarithromycin 9(E)-oxime having purity more than 98% and corresponding (Z)-isomer not more than 1%. The present invention further relates to a process for preparation of Clarithromycin 9(E)-oxime of formula (I), its pharmaceutically acceptable salts and purification.
The present invention relates to an industrial process for the preparation of 3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-carboxylic acid of formula (I). The present invention further involves the preparation of 3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-carboxylic acid of formula (I) using an intermediate of formula (V).
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
C07D 231/06 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
11.
AN INDUSTRIAL PROCESS FOR RESOLUTION OF CHLOCYPHOS
The present invention relates to a process for resolution of Chlocyphos of Formula (I) to obtain corresponding (S)- or (R)-isomers. The present invention further relates to a process of obtaining (S)-Chlocyphos using (R)-(+)-α-methylbenzylamine and (R)-Chlocyphos using (S)-α-methylbenzylamine. The said resolution process provides the corresponding isomer with chiral purity more than 98%.
The present invention relates to a process for resolution of Chlocyphos of Formula (I) to obtain corresponding (S)- or (R)-isomers. The present invention further relates to a process of obtaining (S)-Chlocyphos using (R)-(+)-α-methylbenzylamine and (R)-Chlocyphos using (S)-α-methylbenzylamine. The said resolution process provides the corresponding isomer with chiral purity more than 98%.
The present invention relates to an improved process for the preparation of intermediate of Trifloxystrobin in single isolation stage. The present invention provides an improved process for the preparation of (E)-2-(2-halomethylphenyl)-2-methoxy iminoacetic acid methyl ester of formula (I) in an environment friendly commercially viable manner with greater yield and high chemical purity. (formula I) where X is Cl, Br, F
A01N 37/50 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids the nitrogen atom being doubly bound to the carbon skeleton
C07C 249/12 - Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reactions not involving the formation of oxyimino groups
C07C 251/48 - Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
13.
A SCALABLE PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE GLYCINE TERT-BUTYL ESTER AND ITS SALT THEREOF
The present invention relates to a scalable and efficient process for the preparation of substantially pure Glycine tert-butyl ester. The invention further relates to preparation of substantially pure Glycine tert-butyl ester and its salt of formula (I) using commercially available metal phthalimide, inorganic base and solvent.
C07C 227/06 - Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
14.
AN IMPROVED PROCESS FOR PREPARATION OF PROHEXADIONE AND ITS CALCIUM SALT
The present invention relates to an improved and efficient process for the preparation of Prohexadione and its calcium salt of formula (I). The present invention further relates to a one step process for preparation of ethyl 3,5-dioxo-4-propionyl-cyclohexanecarboxylate a key intermediate of 3,5-dioxo-4-propionyl-cyclohexanecarboxylic acid by avoiding an O-alkylation.
C07C 67/313 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of doubly bound oxygen containing functional groups, e.g. carboxyl groups
C07C 51/41 - Preparation of salts of carboxylic acids by conversion of the acids or their salts into salts with the same carboxylic acid part
C07C 62/38 - Unsaturated compounds containing keto groups
15.
INDUSTRIAL METHOD OF PRODUCING BENZISOTHIAZOLINONE
The present invention relates to an industrial method for the preparation of Benzisothiazolinone formula (I), which is simple, economical, efficient, user and environment friendly, moreover commercially viable with higher yield and chemical purity.
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
C07D 275/04 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
A61K 31/428 - Thiazoles condensed with carbocyclic rings
16.
AN IMPROVED PROCESS FOR PREPARATION OF DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE
The present invention relates to an improved process for preparation of Dapagliflozin propanediol monohydrate of formula (I). The invention further relates to an improved process for the preparation of substantially pure intermediate of formula (VI) having des-bromo impurity of formula (VIII) less than 0.15%.
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
17.
A SIMPLE PROCESS FOR THE PREPARATION OF FAVIPIRAVIR AND ITS INTERMEDIATES THEREOF
The present invention relates to a simple process for the preparation of Favipiravir of Formula (I). The present invention further relates to an improved process for the preparation of substantially pure 2-aminomalonamide of formula (II) a key starting material of Favipiravir.
C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 233/90 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
18.
AN IMPROVED PROCESS FOR PREPARATION OF EMPAGLIFLOZIN AND ITS CRYSTALLINE POLYMORPH
C07D 407/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07C 39/367 - Halogenated derivatives polycyclic non-condensed, containing only six-membered aromatic rings, e.g. halogenated poly-(hydroxy-phenyl)alkanes
C07C 43/225 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
C07C 43/247 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring, other than a six-membered aromatic ring containing halogen
19.
PROCESS FOR THE PREPARATION OF 3,5-DICHLORO-2,2,2-TRIFLUOROACETOPHENONE
The present invention relates to an improved process for the preparation of 3,5-Dichloro-2,2,2-Trifluoroacetophenone of formula (I). The present invention further provides an improved process for the preparation of Fluralaner using 3,5-dichloro-2,2,2-trifluoroacetophenone of formula (I) obtained by a process described herein.
C07C 45/00 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds
C07C 45/30 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
C07C 45/45 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by condensation
C07C 221/00 - Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
20.
PROCESS FOR PREPARATION OF 5-BROMO-1, 2, 3-TRICHLOROBENZENE
The present invention relates to a process for preparation of 5-bromo-1,2,3-trichlorobenzene of formula (I) in simple, economical manner with high yield. The 5-bromo-1,2,3-trichlorobenzene of formula (I) is used in preparation of 1-(3,4,5-trichloro-phenyl)-2,2,2-trifluoro-ethanone which is a key intermediate of isoxazoline derivatives. (I)
The present invention relates to an efficient process for the preparation of Ertugliflozin L-pyroglutamic acid of formula (I) and intermediate thereof, in environment friendly conditions. The present invention further relates to a process for the preparation of substantially pure intermediate of formula (IV).
The present invention relates to an improved process for the preparation of Pregabalin (I), which is simple, economical, efficient, and environment friendly, commercially viable with chemical and chiral purity at least 99.95%.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
C07C 227/04 - Formation of amino groups in compounds containing carboxyl groups
C07C 253/10 - Preparation of carboxylic acid nitriles by addition of hydrogen cyanide or salts thereof to unsaturated compounds to compounds containing carbon-to-carbon double bonds
C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
C12P 41/00 - Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
The present invention relates to a process for purification of Fluralaner of formula (I). The present invention further relates to a process for purification of Fluralaner of formula (I) with purity more than 99%, in simple, economic and commercially viable manner.
The present invention relates to substantially pure Clarithromycin 9-oxime more particularly Clarithromycin 9(E)-oxime having purity more than 98% and corresponding (Z)-isomer not more than 1%. The present invention further relates to a process for preparation of Clarithromycin 9(E)-oxime of formula (I), its pharmaceutically acceptable salts and purification.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
25.
SUBSTANTIALLY PURE CLARITHROMYCIN 9-OXIME AND ITS PREPARATION THEREOF
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
26.
AN INDUSTRIAL SCALE PROCESS FOR THE PREPARATION OF PROTHIOCONAZOLE
The present invention relates to an industrial scale process for the preparation of Prothioconazole (I), which is simple, economical, efficient, user and environment friendly, moreover commercially viable with higher yield and greater chemical purity.
The present invention relates to a process for resolution of Chlocyphos of Formula (I) to obtain corresponding (S)- or (R)- isomers. The present invention further relates to a process of obtaining (S)-Chlocyphos using (R)-(+)-α-methylbenzylamine and (R)-Chlocyphos using (S)-(-)-α-methylbenzylamine. The said resolution process provides the corresponding isomer with chiral purity more than 98%.
C10G 11/18 - Catalytic cracking, in the absence of hydrogen, of hydrocarbon oils with preheated moving solid catalysts according to the "fluidised bed" technique
28.
AN INDUSTRIAL PROCESS FOR RESOLUTION OF CHLOCYPHOS
The present invention relates to a process for resolution of Chlocyphos of Formula (I) to obtain corresponding (S)- or (R)- isomers. The present invention further relates to a process of obtaining (S)-Chlocyphos using (R)-(+)-?-methylbenzylamine and (R)-Chlocyphos using (S)-(-)-?-methylbenzylamine. The said resolution process provides the corresponding isomer with chiral purity more than 98%.
C10G 11/18 - Catalytic cracking, in the absence of hydrogen, of hydrocarbon oils with preheated moving solid catalysts according to the "fluidised bed" technique
29.
AN INDUSTRIAL SCALE PROCESS FOR THE PREPARATION OF PROTHIOCONAZOLE
The present invention relates to an industrial scale process for the preparation of Prothioconazole (I), which is simple, economical, efficient, user and environment friendly, moreover commercially viable with higher yield and greater chemical purity.
The present invention relates to an improved process for the preparation of 2-amino-N-(2,2,2-trifluoroethyl) acetamide of formula (I) and salts (IA) thereof, in an environment friendly and commercially viable manner in high yield and greater chemical purity.
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07D 209/48 - Iso-indolesHydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
31.
PROCESS FOR THE PREPARATION OF A KEY INTERMEDIATE OF GEMFIBROZIL
The present invention relates to an improved process for the preparation of 5-bromo-2,2-dimethyl-pentanoic acid isobutyl ester of formula (I), a key intermediate of Gemfibrozil, by using radical initiator in an environment friendly and commercially viable manner with safer conditions in high yield and high chemical purity.
The present invention relates to an economical, enzyme catalyzed and commercially viable greener process for manufacturing Pregabalin of formula (I) in high yield with highchemical and chiral purity.
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
C07C 253/10 - Preparation of carboxylic acid nitriles by addition of hydrogen cyanide or salts thereof to unsaturated compounds to compounds containing carbon-to-carbon double bonds
C12P 41/00 - Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
The present invention relates to an improved process for the preparation of trifloxystrobin of formula (I), which is simple, economical, efficient, user and environment friendly, moreover commercially viable with higher yield and chemical purity.
C07C 249/08 - Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds
C07C 249/12 - Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reactions not involving the formation of oxyimino groups
B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
The present invention relates to a stable crystalline dioxane solvate of Prothioconazole formula (I) and process for preparation thereof. The present invention also relates to crystalline 1,4-dioxane solvate of prothioconazole (II) and process for preparation thereof.
A01N 43/64 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
C07D 249/02 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
35.
A CO-CRYSTAL OF CANAGLIFLOZIN WITH ALPHA-METHYL-L-PROLINE AND PROCESS FOR THE PREPARATION THEREOF
The present invention relates to a novel alpha-methyl-L-proline co-crystal of canagliflozin (I). The present invention further relates to a process of preparing alpha-methyl-L-proline co-crystal of canagliflozin (I) which is commercially viable process to produce in greater yield and high chemical purity.
C07D 409/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
36.
AN IMPROVED PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
The present invention relates to provide an improved process for the preparation of sitagliptin (I) and its pharmaceutical acceptable salts thereof, which is simple, economical, efficient, user and environment friendly, moreover commercially viable.
The present invention relates to the field of chemistry for the preparation of gabapentin salt of formula (I). More particularly the present invention relates to a continuous process for preparation of gabapentin salt (I) by means of the Hofmann rearrangement reaction using pinch tube reactor in greener and commercially viable manner with safer conditions in high yield and high chemical purity. wherein X is any alkali metal.
The present invention relates to an improved process for the preparation of 5-bromo-2,2- dimethyl-pentanoic acid isobutyl ester of formula (I), a key intermediate of gemfibrozil, in an environment friendly and commercially viable manner with safer conditions in high yield and high chemical purity.
The present invention relates to an improved process for the preparation of trifloxystrobin of formula (I), which is simple, economical, efficient, user and environment friendly, moreover commercially viable with higher yield and chemical purity.
The present invention relates to an improved process for preparing thiabendazole of formula (I) with high yield, high purity, in economical and commercially viable manner for agricultural and pharmaceutical use.
C07D 235/06 - BenzimidazolesHydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates to provide an improved and novel process for the preparation of Apixaban of formula (I), which is simple, economical, metal-free, efficient, user and environment friendly, moreover commercially viable.
C07C 213/00 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
44.
AN IMPROVED PROCESS FOR THE PREPARATION OF BUTORPHANOL TARTRATE
C07C 213/00 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
The present invention provides an improved process for the preparation of a compound of formula (I), which comprises the steps of: formula (I), (a) reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) optionally in presence of salts of weak acid and weak base or weak base in a suitable solvent to get 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV); (b) reacting 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV) with a suitable cyanide source in water or in an organic solvent or mixture thereof to get 2-isobutylsuccinonitrile of formula (V); (c) obtaining optionally 2-isobutylsuccinonitrile of formula (V) by reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) in presence of suitable cyanide source in water or in an organic solvent or mixture thereof in single step; (d) converting 2-isobutylsuccinonitrile of formula (V) to racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) with a genetically modified nitrilase enzyme (Nit 9N_56_2) in water or optionally with an organic co-solvent at appropriate pH and temperature; (e) converting racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) to racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII) by treatment with alcohol (R3OH) and acidic catalyst or alkyl halide (R3X) in presence of a base in a suitable solvent or a mixture of solvents thereof; (f) obtaining (S)-alkyl 3-cyano-5-methyl-hexanoate of formula (VIII) and (R)-3-cyano-5-methyl-hexanoic acid or salt thereof of formula (X) by enzymatic enantioselective hydrolysis in water or organic solvent or a mixture thereof from racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII); (g) obtaining optionally the compound of formula (VII) by racemizing unwanted (R)-3-cyano-5-methyl-hexanoic acid or salt thereof of formula (X) or substantially enriched (R)-3-cyano-5-methyl-hexanoic acid salt thereof of formula (X) in presence of a base in organic solvent or a mixture thereof; (h) converting (S)-alkyl 3-cyano-5-methyl-hexanoate of formula (VIII) to pregabalin of formula (I) by hydrolyzing ester group with suitable alkali or alkaline earth metal base followed by hydrogenation optionally in one pot in a solvent selected from water or other organic solvents or a mixture thereof in presence of a suitable hydrogenation catalyst.
C07C 253/10 - Preparation of carboxylic acid nitriles by addition of hydrogen cyanide or salts thereof to unsaturated compounds to compounds containing carbon-to-carbon double bonds
C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
C12P 41/00 - Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
The present invention relates to a commercially viable novel process for manufacturing Vildagliptin in high yield with high chemical and chiral purity.
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 207/00 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
C07C 211/38 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
The present invention provides an improved process for the preparation of a compound of formula (I), which comprises the steps of: formula (I), (a) reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) optionally in presence of salts of weak acid and weak base or weak base in a suitable solvent to get 2-cyano-5- methyl-hex-2-enoic acid alkyl ester of formula (IV); (b) reacting 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV) with a suitable cyanide source in water or in an organic solvent or mixture thereof to get 2-isobutylsuccinonitrile of formula (V); (c) obtaining optionally 2-isobutylsuccinonitrile of formula (V) by reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) in presence of suitable cyanide source in water or in an organic solvent or mixture thereof in single step; (d) converting 2-isobutylsuccinonitrile of formula (V) to racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) with a genetically modified nitrilase enzyme (Nit 9N_56_2) in water or optionally with an organic co-solvent at appropriate pH and temperature; (e) converting racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) to racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII) by treatment with alcohol (R3OH) and acidic catalyst or alkyl halide (R3X) in presence of a base in a suitable solvent or a mixture of solvents thereof;.(f) obtaining (S)-alkyl 3 -cyano-5 -methyl -hexanoate of formula (VIII) and (R)-3-cyano-5-methyl- hexanoic acid or salt thereof of formula (X) by enzymatic enantioselective hydrolysis in water or organic solvent or a mixture thereof from racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII);.(g) obtaining optionally the compound of formula (VII) by racemizing unwanted (R)-3-cyano-5- methyl-hexanoic acid or salt thereof of formula (X) or substantially enriched (R)-3 -cyano-5 - methyl-hexanoic acid salt thereof of formula (X) in presence of a base in organic solvent or a mixture thereof; (h) converting (S)-alkyl 3-cyano-5-methyl-hexanoate of formula (VIII) to pregabalin of formula (I) by hydrolyzing ester group with suitable alkali or alkaline earth metal base followed by hydrogenation optionally in one pot in a solvent selected from water or other organic solvents or a mixture thereof in presence of a suitable hydrogenation catalyst.
C07C 227/12 - Formation of amino and carboxyl groups
A61P 25/00 - Drugs for disorders of the nervous system
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
The present invention provides an improved process for the preparation of a compound of formula (I), which comprises the steps of: formula (I), (a) reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) optionally in presence of salts of weak acid and weak base or weak base in a suitable solvent to get 2-cyano-5- methyl-hex-2-enoic acid alkyl ester of formula (IV); (b) reacting 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV) with a suitable cyanide source in water or in an organic solvent or mixture thereof to get 2-isobutylsuccinonitrile of formula (V); (c) obtaining optionally 2-isobutylsuccinonitrile of formula (V) by reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) in presence of suitable cyanide source in water or in an organic solvent or mixture thereof in single step; (d) converting 2-isobutylsuccinonitrile of formula (V) to racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) with a genetically modified nitrilase enzyme (Nit 9N_56_2) in water or optionally with an organic co-solvent at appropriate pH and temperature; (e) converting racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) to racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII) by treatment with alcohol (R3OH) and acidic catalyst or alkyl halide (R3X) in presence of a base in a suitable solvent or a mixture of solvents thereof;.(f) obtaining (S)-alkyl 3 -cyano-5 -methyl -hexanoate of formula (VIII) and (R)-3-cyano-5-methyl- hexanoic acid or salt thereof of formula (X) by enzymatic enantioselective hydrolysis in water or organic solvent or a mixture thereof from racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII);.(g) obtaining optionally the compound of formula (VII) by racemizing unwanted (R)-3-cyano-5- methyl-hexanoic acid or salt thereof of formula (X) or substantially enriched (R)-3 -cyano-5 - methyl-hexanoic acid salt thereof of formula (X) in presence of a base in organic solvent or a mixture thereof; (h) converting (S)-alkyl 3-cyano-5-methyl-hexanoate of formula (VIII) to pregabalin of formula (I) by hydrolyzing ester group with suitable alkali or alkaline earth metal base followed by hydrogenation optionally in one pot in a solvent selected from water or other organic solvents or a mixture thereof in presence of a suitable hydrogenation catalyst.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
C07C 229/24 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
The present invention discloses a process for the preparation of dibenzothiazepinone compounds of Formula I. The process for preparation of a dibenzothiazepinone compound of Formula I comprises reaction of compound of formula II in the presence of an acid catalyst comprising phosphorus pentoxide and methanesulfonic acid. The dibenzothiazepinone compounds of Formula I are key intermediate for the preparation of 2-(2-(4-dibenzo[b,f][1,4]thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol known as quetiapine and its derivatives, which are effective antipsychotic substances.
The invention describes an improved method for producing halo-dialkoxybenzenes of formula (I) such as 1-fluoro-2, 3-dialkoxybenzene as well as 2-fluoro-1, 4-dialkoxybenzene, Formula (I) by reacting commercial 2-fluorophenol is reacted with an allyl halide in N-methylpyrrolidone (NMP) followed by rearranging the resultant 2-fluoroallylphenylether to form 2-allyl-6-fluorophenol and its para isomeric counterpart. This compound mixture is then directly alkylated to form isomeric substituted allyl alkoxybenzenes and subjected to isomerization to form the corresponding propenyl derivatives. All the above four steps are carried out without any workup except one filtration. 6-Fluoro-2-propenyl alkyl phenyl ether is separated from the other isomer by a fractional distillation in good yields. The isomers are oxidized to the corresponding benzaldehydes using oxidants in presence of a halo hydrocarbon solvent. The benzaldehydes is further oxidised with an organic or an inorganic peroxide in a halo hydrocarbon solvent to obtain the corresponding phenols, which is thereby alkylated to form compound of formula (I).
C07C 37/055 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis by substitution of a group bound to the ring by oxygen, e.g. ether group
C07C 39/27 - Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being attached to the ring
C07C 41/16 - Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
C07C 41/26 - Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
C07C 41/32 - Preparation of ethers by isomerisation
C07C 41/42 - SeparationPurificationStabilisationUse of additives by change of physical state, e.g. by crystallisation by distillation
C07C 43/225 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
C07C 43/23 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
C07C 45/29 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation of hydroxy groups
C07C 47/575 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing ether groups, groups, groups, or groups
52.
A PROCESS FOR PREPARATION OF PHENETHYLAMINE DERIVATIVE
The present invention relates to a process for the preparation of 1-[2-amino-1-(4-substituted phenyl)ethyl]cyclohexanol (3) (where R is OMe, OH), said process comprising the steps of; subjecting a reaction mixture of substituted phenylacetonitrile (2) in alcohol, an organic acid, and a hydrogenating catalyst in the presence of hydrogen gas pressure in the range of 0.5 kg/cm2 to 30 kg/cm2 and temperature in the range of 0-100°C; filtering and concentrating the cooled reaction mixture to obtain an acid addition salt of 1-[2-amino-1-(4-substituted phenyl)ethyl]cyclohexanol (4); and treating the acid addition salt of 1-[2-amino-1-(4-substituted phenyl)ethyl]cyclohexanol (4) with an ester in presence of a base to obtain 1-[2-amino-1-(4-substituted phenyl) ethyl] cyclohexanol (3).
C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
C07C 217/74 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
53.
CRYSTALLINE FORMS OF GABAPENTIN AND PROCESS FOR THEIR PREPARATION
The present invention relates to crystalline forms of gabapentin and processes for preparing the same. The present invention particularly relates to crystalline forms of gabapentin form II and Form IIB. The invention also relates to gabapentin form IA and form IB. The gabapentin forms IA and IB are hydrated forma that contain about 20% of water by weight which corresponds to hemipentahydrate. The present invention also relates to the process for preparing these crystalline forms of gabapentin.
C07C 229/28 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
54.
A PROCESS FOR THE PREPARATION OF 2-CYANOIMINO-1,3-THIAZOLIDINE
The present invention relates to a process for the preparation of substantially pure 2-cyanoimino-1, 3-thiazolidine of Formula (I) by cyclization of dimethyl N-cyanoiminodithiocarbonate with 2-aminoethanethiol or the salt thereof in the presence of an alkali metal alkoxide. Further the present invention provides a process for the preparation of substantially pure 2-cyanoimino-1, 3-thiazolidine of Formula (I) by cyclization of dimethyl N-cyanoiminodithiocarbonate with 2-aminoethanethiol or the salt thereof in the presence of aqueous ammonia.
A process for preparation of E-isomer of 1-(4-methylphenyl)-1-(2-pyridyl)-3- pyrrolidinoprop-1-ene of Formula-I, and acid addition salts thereof, said process comprising; dehydrating 1-(4-methylphenyl)-l -(2-pyridyl)-3-pyrrolidinopropan-1-ol of Formula III followed by adding a base solution to obtain a mixture of E and Z isomers of 1-(4-methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene, and washing said mixture of E and Z isomers of 1-(4-methylphenyl)-1-(2-pyridyl)-3- pyrrolidinoprop-1-ene with water to dissolve Z isomer and to obtain E-isomer of 1- (4-methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene of Formula I, which is substantially free from Z isomer.
patents
